Since 1984, high-dose IL-2 has been used to treat malignant melanoma patients with tumor regression.215 In 1992 and 1998, the FDA approved IL-2 for the treatment of metastatic renal cell carcinoma and metastatic melanoma, respectively. Here, IL2 is linked to melanoma.